Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 2Sarcoma, Kaposi 1Sarcoma 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Neurofibromatosis 1 1Neoplasm Metastasis 1Liposarcoma 1Leiomyosarcoma 1Glioma 1Colorectal Neoplasms 1Brain Neoplasms 1Acquired Immunodeficiency Syndrome 1

Interventions

Fluorouracil 61Leucovorin 56Oxaliplatin 36Irinotecan 27Specimen Handling 23Biopsy 20Chemotherapy, Adjuvant 17Capecitabine 14Cetuximab 13Magnetic Resonance Spectroscopy 12Folfox protocol 12Bevacizumab 12Neoadjuvant Therapy 10sargramostim 6aldesleukin 6Melphalan 6Radiotherapy 5Floxuridine 5Cyclophosphamide 5dehydroftorafur 4X-Rays 4Nivolumab 4Interferon-alpha 4Immunoglobulin G 4Gemcitabine 4Disulfides 4Celecoxib 4fludarabine 3durvalumab 3Trastuzumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Colorectal Neoplasms × abemaciclib × Clear all
NCT06654037 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
39 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡